Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 66, Issue 1, Pages 1-7Publisher
SPRINGER
DOI: 10.1007/s00262-016-1909-3
Keywords
Immunotherapy; Tumor-directed immunotherapy; Cancer; Intratumoral; Bispecific antibody; Immuno-oncology
Categories
Funding
- Alligator Bioscience AB
Ask authors/readers for more resources
The most important goals for the field of immuno-oncology are to improve the response rate and increase the number of tumor indications that respond to immunotherapy, without increasing adverse side effects. One approach to achieve these goals is to use tumor-directed immunotherapy, i.e., to focus the immune activation to the most relevant part of the immune system. This may improve anti-tumor efficacy as well as reduce immune-related adverse events. Tumor-directed immune activation can be achieved by local injections of immune modulators in the tumor area or by directing the immune modulator to the tumor using bispecific antibodies. In this review, we focus on therapies targeting checkpoint inhibitors and co-stimulatory receptors that can generate tumor-specific T cell responses through localized immune activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available